Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part II. Diagnosis and management

J Am Acad Dermatol. 2024 Jul;91(1):13-22. doi: 10.1016/j.jaad.2023.08.084. Epub 2023 Sep 14.

Abstract

In the second part of this Continuing Medical Education article on paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome (PNP/PAMS), its diagnostic criteria, investigative work-up, and management are reviewed. PNP/PAMS is a rare autoimmune blistering disorder associated with high morbidity and mortality. Recognizing PNP/PAMS's key features and its diagnostic criteria is critical in initiating appropriate work-up. Evaluating PNP/PAMS requires knowledge of its findings on histopathology, direct immunofluorescence, indirect immunofluorescence, and enzyme-linked immunosorbent assay. Lastly, treatments for PNP/PAMS are reviewed with suggestions based on case reports and expert opinions in the literature.

Keywords: ELISA; PAMS; criteria; diagnosis; histopathology; paraneoplastic; paraneoplastic autoimmune syndrome; pemphigus; therapy; treatment.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases / complications
  • Autoimmune Diseases / diagnosis
  • Autoimmune Diseases / therapy
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Multiple Organ Failure / diagnosis
  • Multiple Organ Failure / etiology
  • Paraneoplastic Syndromes* / diagnosis
  • Paraneoplastic Syndromes* / etiology
  • Pemphigus* / diagnosis
  • Pemphigus* / therapy

Substances

  • Immunosuppressive Agents